October 26, 2022
October 26, 2022
Categories

Press Release: NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib

Do you like it?
Read more
October 21, 2022
October 21, 2022
Categories

Press Release: Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting to assess the stage of disease more accurately using standard CT scans

Do you like it?
Read more
October 13, 2022
October 13, 2022
Categories

The September/October 2022 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
October 4, 2022
October 4, 2022
Categories

DREAMseq trial clarifies immunotherapy, targeted treatment order for patients with BRAF-mutant metastatic melanoma

Do you like it?
Read more
September 30, 2022
September 30, 2022
Categories

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

Do you like it?
Read more
September 28, 2022
September 28, 2022
Categories

Immunotherapy before targeted therapy improves survival in advanced melanoma, according to the DREAMseq trial

Do you like it?
Read more
September 27, 2022
September 27, 2022
Categories

Media Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma

Do you like it?
Read more
September 26, 2022
September 26, 2022
Categories

The Fall 2022 advocacy blog Considering Clinical Trials is now available

Do you like it?
Read more
September 8, 2022
September 8, 2022
Categories

Press Release: ECOG-ACRIN completes the first randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

Do you like it?
Read more
Load more
ECOG-ACRIN Cancer Research Group